Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00028847 | Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 60 | Commissie Voor Klinisch Toegepast OnderzoekOTHER | 2 | Sep 17, 2013 | clinicaltrials |
| NCT00176475 | Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease | terminated | Phase 1 | 2 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Sep 17, 2013 |
| clinicaltrials |
| NCT00324597 | AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma | unknown | Phase 1 | 18 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 17, 2013 | clinicaltrials |
| NCT00544999 | Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia | unknown | Phase 1 | 21 | Institut de Recherche Clinique sur les Cancers et le SangOTHER | 1 | Sep 17, 2013 | clinicaltrials |
| NCT00996359 | Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation | terminated | Phase 1 | 4 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Sep 17, 2013 | clinicaltrials |
| NCT00046488 | Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL) | completed | Phase 1 | 70 | BiogenINDUSTRY | 1 | Sep 16, 2013 | clinicaltrials |
| NCT00048555 | Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 90 | BiogenINDUSTRY | 1 | Sep 16, 2013 | clinicaltrials |
| NCT01701375 | A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia | terminated | Phase 1 | 2 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 9, 2013 | clinicaltrials |
| NCT00738829 | Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL | completed | Phase 1 / Phase 2 | 45 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Aug 30, 2013 | clinicaltrials |
| NCT00457574 | Safety and Efficacy of GMX1777 in the Treatment of Refractory Solid Tumors or Lymphomas | withdrawn | Phase 1 | 0 | Gemin XINDUSTRY | 0 | Aug 28, 2013 | clinicaltrials |
| NCT00718757 | Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies | completed | Phase 1 | 4 | St. Jude Children's Research HospitalOTHER | 1 | Aug 28, 2013 | clinicaltrials |
| NCT00562068 | Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma | unknown | Phase 1 | 30 | Cancer Research UKOTHER | 1 | Aug 26, 2013 | clinicaltrials |
| NCT00829205 | Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment | withdrawn | Phase 1 / Phase 2 | 0 | Cancer Research UKOTHER | 1 | Aug 26, 2013 | clinicaltrials |
| NCT00947388 | Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) | terminated | Phase 1 | 9 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 22, 2013 | clinicaltrials |
| NCT00001251 | Phase I Study of Intrathecal Mafosfamide | completed | Phase 1 | 65 | National Cancer Institute (NCI)NIH | 1 | Aug 19, 2013 | clinicaltrials |
| NCT01212341 | Allogeneic Natural Killer (NK) Cell Therapy in Patients With Lymphoma or Solid Tumor(MG4101) | completed | Phase 1 | 18 | Seoul National University HospitalOTHER | 1 | Aug 19, 2013 | clinicaltrials |
| NCT00304018 | Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer | completed | Phase 1 | 5 | University of California, San FranciscoOTHER | 1 | Aug 14, 2013 | clinicaltrials |
| NCT01232712 | A Study to Assess the Safety and Efficacy of MUC1 Peptide Vaccine and hGM-CSF in Patients With MUC1-positive Tumor Malignancies | completed | Phase 1 / Phase 2 | 15 | Vaxil Therapeutics Ltd.INDUSTRY | 1 | Aug 9, 2013 | clinicaltrials |
| NCT00008021 | Monoclonal Antibody Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma | unknown | Phase 1 | — | University of California, DavisOTHER | 1 | Aug 7, 2013 | clinicaltrials |
| NCT00003268 | Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 1 | — | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Aug 2, 2013 | clinicaltrials |
| NCT01118689 | Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia | completed | Phase 1 | 39 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2013 | clinicaltrials |
| NCT00006340 | Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus | completed | Phase 1 | — | Boston Medical CenterOTHER | 4 | Jul 26, 2013 | clinicaltrials |
| NCT00507442 | Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients(EVOLUTION) | completed | Phase 1 / Phase 2 | 158 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 26, 2013 | clinicaltrials |
| NCT00369226 | Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 45 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 25, 2013 | clinicaltrials |
| NCT00749502 | A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8) | completed | Phase 1 | 113 | Tesaro, Inc.INDUSTRY | 0 | Jul 25, 2013 | clinicaltrials |
| NCT01728389 | Intrabone Transplantation of Allogenic Peripheral Blood Stem Cells in Patients With Myeloid and Lymphoid Malignancies. | unknown | Phase 1 / Phase 2 | 10 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Jul 24, 2013 | clinicaltrials |
| NCT01161550 | Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML(CLAG ATRA AML) | completed | Phase 1 | 11 | Washington University School of MedicineOTHER | 1 | Jul 23, 2013 | clinicaltrials |
| NCT00872976 | Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia | withdrawn | Phase 1 | 0 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 22, 2013 | clinicaltrials |
| NCT00002543 | Gallium Nitrate in Treating Children With Brain Tumor, Neuroblastoma, Rhabdomyosarcoma, Non-Hodgkin's Lymphoma, or Refractory Solid Tumors | completed | Phase 1 | 3 | Medical College of WisconsinOTHER | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00025129 | VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | — | Vion PharmaceuticalsINDUSTRY | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00049686 | VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | — | Vion PharmaceuticalsINDUSTRY | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00049699 | VNP40101M in Treating Patients With Advanced or Metastatic Cancer | completed | Phase 1 | — | Vion PharmaceuticalsINDUSTRY | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00064090 | 3-AP and Cytarabine in Treating Patients With Hematologic Cancer | completed | Phase 1 | — | Vion PharmaceuticalsINDUSTRY | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00070538 | VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies | completed | Phase 1 | — | Vion PharmaceuticalsINDUSTRY | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00098436 | Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias | completed | Phase 1 | 25 | Vion PharmaceuticalsINDUSTRY | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00304005 | VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders | completed | Phase 1 / Phase 2 | 35 | Vion PharmaceuticalsINDUSTRY | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00562380 | AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma | completed | Phase 1 | 64 | AmgenINDUSTRY | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00723359 | Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 32 | Biotest Pharmaceuticals CorporationINDUSTRY | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00697671 | Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies | completed | Phase 1 | 48 | St. Jude Children's Research HospitalOTHER | 1 | Jul 16, 2013 | clinicaltrials |
| NCT00005021 | Combination Chemotherapy With or Without Biological Therapy in Treating Patients With Refractory Solid Tumor or Lymphoma | completed | Phase 1 | 17 | Fox Chase Cancer CenterOTHER | 1 | Jul 11, 2013 | clinicaltrials |
| NCT00871702 | Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease | completed | Phase 1 | 12 | Washington University School of MedicineOTHER | 1 | Jul 11, 2013 | clinicaltrials |
| NCT00098332 | Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma | completed | Phase 1 | — | BioCryst PharmaceuticalsINDUSTRY | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00100997 | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate | completed | Phase 1 | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT01371227 | A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 3 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Jul 4, 2013 | clinicaltrials |
| NCT00012181 | Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00377104 | Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | terminated | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00807677 | A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies | completed | Phase 1 | 31 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00994500 | Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00009698 | Interleukin-2 in Treating Children Who Have Undergone Bone Marrow Transplantation for Acute Myeloid Leukemia | completed | Phase 1 | 1 | Children's Oncology GroupNETWORK | 6 | Jun 28, 2013 | clinicaltrials |
| NCT00003619 | Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | — | Drexel University College of MedicineOTHER | 1 | Jun 26, 2013 | clinicaltrials |
Data updated 24 days agoSource updated Sep 17, 2013source: clinicaltrials